Cocrystal Net Working Capital from 2010 to 2025

COCP Stock  USD 1.56  0.01  0.65%   
Cocrystal Pharma Net Working Capital yearly trend continues to be relatively stable with very little volatility. Net Working Capital is likely to drop to about 25.7 M. During the period from 2010 to 2025, Cocrystal Pharma Net Working Capital destribution of quarterly values had range of 57 M from its regression line and mean deviation of  15,818,615. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
29.7 M
Current Value
25.7 M
Quarterly Volatility
18.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cocrystal Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cocrystal Pharma's main balance sheet or income statement drivers, such as Interest Expense of 1.7 K, Selling General Administrative of 4.1 M or Selling And Marketing Expenses of 8.9 M, as well as many indicators such as Price To Sales Ratio of 383, Dividend Yield of 0.0 or PTB Ratio of 0.69. Cocrystal financial statements analysis is a perfect complement when working with Cocrystal Pharma Valuation or Volatility modules.
  
Check out the analysis of Cocrystal Pharma Correlation against competitors.
To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

Latest Cocrystal Pharma's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Cocrystal Pharma over the last few years. It is Cocrystal Pharma's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cocrystal Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Cocrystal Net Working Capital Regression Statistics

Arithmetic Mean14,008,992
Geometric Mean3,743,398
Coefficient Of Variation130.77
Mean Deviation15,818,615
Median1,386,000
Standard Deviation18,319,289
Sample Variance335.6T
Range57M
R-Value0.74
Mean Square Error161.1T
R-Squared0.55
Significance0.001
Slope2,858,596
Total Sum of Squares5033.9T

Cocrystal Net Working Capital History

202525.7 M
202429.7 M
202325.8 M
202239 M
202157.8 M
202032.7 M
2019M

About Cocrystal Pharma Financial Statements

Cocrystal Pharma shareholders use historical fundamental indicators, such as Net Working Capital, to determine how well the company is positioned to perform in the future. Although Cocrystal Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Cocrystal Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Cocrystal Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working Capital29.7 M25.7 M

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.